Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Revenue Growth: Approximately 30% revenue growth in Q4 2025. Full Year Revenue: Total revenue of $264 million for 2025, a 61% increase over the prior year. Q4 Product Revenue: $87 million, a 30% increase from the prior quarter. Gross Margin: Improved to 50% in Q4 2025 from 43% in Q3 2025. Cash Position: Approximately $303 million at year-end 2025. Cash Runway: Extended into the third quarter of 2027. Product Revenue Growth: Imagi revenue growth of 112% year over year. Operational Efficiency: Full internalization of manufacturing operations at ICTC. Fast Track Designation: Granted by FDA for Lielluil in non-small cell lung cancer. Clinical Response Rate: 50% confirmed response rate in advanced soft tissue sarcomas. Warning! GuruFocus has detected 4 Warning Signs with IOVA. Is IOVA fairly valued? Test your thesis with our free DCF calculator. Release Date: February 24, 2026 For the complete transcript of the earnings
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (IOVA) had its price target raised by Barclays PLC from $10.00 to $11.00. They now have an "overweight" rating on the stock.MarketBeat
- Iovance Biotherapeutics (IOVA) had its price target lowered by Chardan Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "outperform". They now have a $5.00 price target on the stock.MarketBeat
- Iovance Biotherapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade) [Seeking Alpha]Seeking Alpha
IOVA
Earnings
- 2/24/26 - Beat
IOVA
Sec Filings
- 2/24/26 - Form 10-K
- 2/24/26 - Form 8-K
- 2/12/26 - Form 4
- IOVA's page on the SEC website